It is noted that the results of the study were published in the leading international journal Vaccines.
Scientific Research Center of Epidemiology and Microbiology named after N.F.
Gamaleis of the Ministry of Health of Russia and the Russian Direct Investment Fund announce positive results of a study of the neutralizing activity of blood serum taken from those vaccinated with Sputnik V against new strains of SARS-CoV-2, ”the RDIF reported.
The head of the Gamaleya Center, Alexander Gunzburg, noted that Sputnik V is effective due to an approach based on the use of two different adenoviral vectors as delivery tools.
According to the head of RDIF, Kirill Dmitriev, the studies have shown that the virus-neutralizing activity of Sputnik V against new, more dangerous strains was higher than that of many other Western vaccines.
According to him, the foundation will continue to support further research on the effectiveness of the Russian vaccine against new strains.
Earlier, RDIF announced the high safety performance of Sputnik V in San Marino.